Polygenic Risk Score Series | Discover How PRSs Will Impact Clinical Care

8 May 2019

In chapter 4, industry thought leaders explore how polygenic risk scores will one day impact clinical care—as early predictors of disease, when there is an unclear diagnosis, and early detection of cancer are a few possible applications. Hear from Professor of Statistical Genetics David Evans, Professor of Quantitative Genetics Peter Visscher, Geneticist Gerome Breen, Professor of Psychiatric and Quantitative Genetics Naomi Ray, and Representative Director of Genome Analytics Japan Co., Ltd. Tsuyoshi Hachiya. Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

Share this article on